热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　再鼎医药（09688）发布截至2024年12月31日止年度年度业绩，总收入3.99亿美元，同比增加49.59%；研发开支2.35亿美元。

　　公告称，收入增长主要是由于卫伟迦自2023年9月强势商业化上市并于2024年1月首次被纳入国家医保目录以来其销售额稳步增长；则乐继续保持卵巢癌领域PARP抑制剂院内销售领军者地位；以及得益于纽再乐用于治疗CABP及╱或ABSSSI的静脉注射剂型及用于该等适应证的口服剂型分别于2023年1月及2024年1月被纳入国家医保目录。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.